cox 189 has been researched along with naproxen in 20 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 4,551 | 1,057 | 1,429 |
| Protein | Taxonomy | cox 189 (IC50) | naproxen (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.1642 | |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | 1.2 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.0203 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.8725 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.06 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.5867 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 1.26 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.36 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 5.8 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (75.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Branson, J; Ford, M; Kellett, N; Mair, S; Milosavljev, S; Rordorf, C; Scott, G | 1 |
| Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P | 1 |
| Summerton, N | 1 |
| Alten, R; Geusens, P; Kralidis, G; Krammer, G; Richardson, P; Rovensky, J; Sloan, VS | 1 |
| Chan, VW; Clark, AJ; Davis, JC; Jayawardene, S; Kellstein, D; Wolf, RS | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM | 1 |
| Hawkey, CJ; Krammer, G; Murphy, V; Rebuli, R; Richard, D; Stricker, K; Weinstein, WM | 1 |
| Albert, J; Arulmani, U; Bolten, W; Ell, C; Fortun, P; Hawkey, CJ; Hugot, JL; Keuchel, M; Krammer, G; McAlindon, M; Rebuli, R; Schumann, S; Shonde, A; Simon, B; Toth, E; Yu, V | 1 |
| Barton, S; Daniels, S; Gitton, X; Stricker, K; Zhou, W | 1 |
| Chesebro, JH; Farkouh, ME; Gitton, X; Jeger, R; Kirshner, H; Krammer, G; Matchaba, P; Mellein, B; Ruland, S; Sallstig, P; Stricker, K; Verheugt, FW | 1 |
| Adekunle, F; Andrews, C; Ellis, G; Kinch, H; Kyle, C; Zachariah, J | 1 |
| Bertinaria, M; Buccellati, C; Capra, V; Carnevali, S; Cena, C; Fruttero, R; Garella, D; Hoxha, M; Rolando, B; Rovati, GE; Sala, A | 1 |
3 review(s) available for cox 189 and naproxen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
11 trial(s) available for cox 189 and naproxen
| Article | Year |
|---|---|
Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
Topics: Adolescent; Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Endoscopy, Gastrointestinal; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Pilot Projects; Prostaglandin-Endoperoxide Synthases; Thromboxanes | 2003 |
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Health Status; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Prognosis; Prostaglandin-Endoperoxide Synthases; Risk Factors | 2004 |
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Organic Chemicals; Pain Measurement; Treatment Outcome | 2004 |
The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Morphine; Naproxen; Organic Chemicals; Pain Measurement; Pain, Postoperative; Sample Size | 2005 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis | 2007 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Ulcer; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Risk Reduction Behavior; Stomach Ulcer | 2007 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Statistics as Topic | 2008 |
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
Topics: Administration, Oral; Adult; Aged; Capsule Endoscopes; Cross-Over Studies; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Reference Values; Risk Assessment; Ulcer | 2008 |
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dysmenorrhea; Female; Humans; Middle Aged; Naproxen; Pain Measurement; Treatment Outcome | 2008 |
A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Creatinine; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Pain Measurement | 2008 |
A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
Topics: Acute Disease; Adult; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Musculoskeletal Diseases; Naproxen; Pain; Treatment Outcome | 2008 |
6 other study(ies) available for cox 189 and naproxen
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evidence in practice--number 3: Cox 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medicine; Humans; Ibuprofen; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Stomach Ulcer | 2004 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adolescent; Adult; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; HEK293 Cells; Humans; Male; Middle Aged; Naphthalenes; Naproxen; Propionates; Receptors, Thromboxane; Young Adult | 2016 |